Cypherpunk Technologies is trading 5.87% up now at $0.72 after reporting second-quarter 2026 net income of $39.4 million, or $0.18 per diluted share, versus a $16.6 million loss last year.
- Results were boosted by a $46.0 million unrealized gain on Zcash treasury holdings.
- Its biotechnology subsidiary reached FDA alignment on a registrational Phase 3 trial.
- Bitcoin and Ethereum are up only 0.49% and 1.34% since the prior close, so company-specific news appears primary.